UBS analyst Ashwani Verma reiterated a Buy rating and $194.00 price target on Insmed (NASDAQ: INSM).The analyst commented, "We see ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE